Different effects of continuous and intermittent patterns of growth hormone administration on lipoprotein levels in growth hormone-deficient patients.

Plain-language guide to PMID 9873197 (1998): double-blind randomized controlled trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 10 patients.

Key Facts

PMID: 9873197
Journal: Hormone research
Year: 1998
Study type: Randomized Controlled Trial
Authors: Laursen T et al. (5 authors)
DOI: 10.1159/000023292

What This Study Did, in Plain Language

What Was Tested

The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a randomized controlled trial.

The aim of the present studies was to describe the impact of intermittent and continuous patterns of GH delivery to GHD patients on serum levels of Lp(a) and other lipoproteins.

Why It Was Studied

Lipoprotein (a) (Lp(a)) is a risk marker for the development of atherosclerotic coronary heart disease.

Who Took Part

The study group was 10 patients.

By PubMed's age tags, the people studied were teenagers, adults and middle-aged adults, both men and women.

How the Study Was Run

The design is described as randomized, double-blind and crossover.

The patients were allocated by chance, so the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group and the comparison group should start out alike.

As a double-blind Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study, the assignments were hidden from both participants and investigators until the end.

In the crossover set-up each of the patients took both Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and the comparison in turn, acting as their own control.

Each study lasted 36 h and was preceded by at least 4 weeks without GH.

What Was Measured

Topics PubMed links to this paper include Cholesterol, Cholesterol, HDL, Cholesterol, LDL, Human Growth Hormone and Lipoprotein(a).

What This Means in Plain Language

The paper is a randomized, double-blind and crossover study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 10 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 9 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 1998 (Hormone research), a journal based in Switzerland.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.

Our Notes on the Compound

Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.

Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in the library

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.